Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Vertex Pharmaceuticals
Vertex Pharmaceuticals
Where Will Vertex Pharmaceuticals Be in 10 Years?
Where Will Vertex Pharmaceuticals Be in 10 Years?
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
exa-cel
sickle cell disease
Flag link:
What to know about the U.K.’s approval of the first CRISPR treatment for diseases
What to know about the U.K.’s approval of the first CRISPR treatment for diseases
Nature
UK
CRISPR
gene editing
Casgevy
Vertex Pharmaceuticals
CRISPR Therapeutics
Flag link:
Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK
Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK
BioSpace
CRISPR
gene editing
Vertex Pharmaceuticals
CRISPR Therapeutics
UK
Casgevy
beta thalassemia
Flag link:
Cell & Gene Therapy Space Gears Up for First CRISPR Approval
Cell & Gene Therapy Space Gears Up for First CRISPR Approval
BioSpace
CRISPR
gene therapy
cell therapy
sickle cell disease
exa-cel
Vertex Pharmaceuticals
CRISPR Therapeutics
Flag link:
Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says
Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says
Fierce Pharma
Bluebird Bio
Vertex Pharmaceuticals
exa-cel
lovo-cel
sickle cell disease
drug pricing
Flag link:
As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations
As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations
Fierce Pharma
Vertex Pharmaceuticals
CRISPR
gene editing
FDA
exa-cel
Flag link:
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
Yahoo/Reuters
Vertex Pharmaceuticals
CRISPR Therapeutics
FDA
gene therapy
exa-cel
Flag link:
Tracking the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
Tracking the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
BioPharma Dive
FDA
Vertex Pharmaceuticals
CRISPR
sickle cell disease
exa-cel
Flag link:
FDA Flags Off-Target Effects of Vertex, CRISPR’s Sickle Cell Therapy Ahead of Adcomm
FDA Flags Off-Target Effects of Vertex, CRISPR’s Sickle Cell Therapy Ahead of Adcomm
BioSpace
Vertex Pharmaceuticals
exa-cel
CRISPR
sickle cell disease
FDA
Flag link:
Vertex gearing up for launch as sickle cell therapy review advances
Vertex gearing up for launch as sickle cell therapy review advances
BioPharma Dive
Vertex Pharmaceuticals
sickle cell disease
exa-cel
Flag link:
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
Businesswire
Vertex Pharmaceuticals
VX-880
clinical trials
type 1 diabetes
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
Vertex gets in on GPCR game, paying Septerna $47M for undisclosed program
Vertex gets in on GPCR game, paying Septerna $47M for undisclosed program
Fierce Biotech
Vertex Pharmaceuticals
GPCRs
Septerna
Flag link:
Promising Vertex Pain Med Points to New Era for Analgesics
Promising Vertex Pain Med Points to New Era for Analgesics
BioSpace
Vertex Pharmaceuticals
VX-548
NEJM
painkillers
post-surgical pain
Flag link:
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center
Fierce Biotech
Vertex Pharmaceuticals
cell therapy
gene therapy
R&D
Boston
Flag link:
First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results
First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results
Clinical Trials Arena
Vertex Pharmaceuticals
exa-cel
CRISPR
beta thalassemia
Flag link:
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
Yahoo/Reuters
Vertex Pharmaceuticals
cystic fibrosis
earnings
Flag link:
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
Reuters
ICER
gene therapy
Vertex Pharmaceuticals
CRISPR Therapeutics
Bluebird Bio
drug pricing
sickle cell disease
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Flag link:
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
BioSpace
gene editing
Editas Medicine
Vertex Pharmaceuticals
CRISPR Therapeutics
EDIT-301
sickle cell disease
beta thalassemia
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »